In the recent BREAKWATER study, encorafenib plus cetuximab plus chemotherapy was compared with standard of care (chemotherapy with or without bevacizumab) in patients with BRAF V600E–mutant metastatic colorectal cancer. Results were provided in an oral abstract recently presented at the 2025 ASCO Gastrointestinal Cancers Symposium.
